Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
Holding TARA?
Track your performance easily
TARA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $10.48
Previous CloseN/A
Volume145.20K
Average Volume (3M)4.67M
Market Cap
$158.90M
Enterprise Value-$35.90M
Total Cash (Recent Filing)$21.87M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 05, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding34,319,770
10 Day Avg. Volume418,886
30 Day Avg. Volume4,674,449
Standard Deviation0.31
R-Squared0.07
Alpha-0.00085
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.94
Forecast
1Y Price Target
$24.00Price Target Upside427.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Protara Therapeutics News
PremiumCompany Announcements
Protara Therapeutics Outlines 2025 Milestones After Fundraising
PremiumCompany Announcements
Protara Therapeutics Raises $100M in Stock OfferingOwnership Overview
10.05% Insiders
2.82% Mutual Funds
21.95% Other Institutional Investors
62.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $1.59 and its highest was $10.48 in the past 12 months.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market cap is $158.90M.
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Mar 05, 2025 which is in 46 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.02.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -0.57.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 34,319,770 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Among the largest hedge funds holding Protara Therapeutics’s share is RA Capital Management. It holds Protara Therapeutics’s shares valued at 3M.
---
Protara Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (427.47% Upside)
$24.00 (427.47% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 751.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.88%
12-Months-Change
Fundamentals
Return on Equity
-52.97%
Trailing 12-Months
Asset Growth
6.36%
Trailing 12-Months
Company Description
Protara Therapeutics
ArTara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.
---
TARA Stock 12 Month Forecast
Average Price Target
$24.00
▲(427.47% Upside)
Technical Analysis
Fennec Pharmaceuticals
―
Eloxx Pharmaceuticals
―
Protalix
―
ADMA Biologics
―
Karyopharm Therapeutics
―
Aurinia Pharmaceuticals
―
Best Analysts Covering TARA
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+48.06%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +48.06% per trade.
---